Human STEAP2 blocking peptide (CDBP2840)

Synthetic Human STEAP2 blocking peptide for BL

Product Overview
Blocking peptide for anti-STEAP2 antibody
Target
STEAP2
Nature
Synthetic
Species Reactivity
Human
Tag/Conjugate
Unconjugated
Application Notes
For in vitro research use only. Not intended for any diagnostic or therapeutic purpose. Not suitable for human or animal consumption.
Procedure
None
Format
Liquid
Concentration
200 μg/ml
Size
50 μg
Buffer
PBS containing 0.02% sodium azide
Preservative
0.02% Sodium Azide
Storage
Store at -20℃, stable for one year.
UniProt ID
Antigen Description
This gene is a member of the STEAP family and encodes a multi-pass membrane protein that localizes to the Golgi complex, the plasma membrane, and the vesicular tubular structures in the cytosol. A highly similar protein in mouse has both ferrireductase and cupric reductase activity, and stimulates the cellular uptake of both iron and copper in vitro. Increased transcriptional expression of the human gene is associated with prostate cancer progression. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
Function
electron carrier activity; flavin adenine dinucleotide binding; iron ion binding; metal ion binding; nucleotide binding; oxidoreductase activity; transporter activity;
Synonyms
STEAP2; STEAP family member 2, metalloreductase; PCANAP1, prostate cancer associated protein 1 , six transmembrane epithelial antigen of the prostate 2; metalloreductase STEAP2; IPCA 1; STAMP1; STMP; prostate cancer associated protein 1; prostate cancer-associated protein 1; SixTransMembrane Protein of Prostate 1; protein upregulated in metastatic prostate cancer; protein up-regulated in metastatic prostate cancer; six transmembrane epithelial antigen of prostate 2; six-transmembrane epithelial antigen of prostate 2; six transmembrane epithelial antigen of the prostate 2; IPCA1; PUMPCn; PCANAP1;

Citations


Have you cited CDBP2840 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Mechanistic analysis of iron accumulation by endothelial cells of the BBB

BIOMETALS

Authors: McCarthy, Ryan C.; Kosman, Daniel J.

The mechanism(s) by which iron in blood is transported across the blood-brain barrier (BBB) remains controversial. Here we have examined the first step of this trans-cellular pathway, namely the mechanism(s) of iron uptake into human brain microvascular endothelial cells (hBMVEC). We show that hBMVEC actively reduce non-transferrin bound Fe-III (NTBI) and transferrin-bound Fe-III (TBI); this activity is associated with one or more ferrireductases. Efficient, exo-cytoplasmic ferri-reduction from TBI is dependent upon transferrin receptor (TfR), also. Blocking holo-Tf binding with an anti-TfR antibody significantly decreases the reduction of iron from transferrin by hBMVEC, suggesting that holo-Tf needs to bind to TfR in order for efficient reduction to occur. Ferri-reduction from TBI significantly decreases when hBMVEC are pre-treated with Pt-II, an inhibitor of cell surface reductase activity. Uptake of Fe-59 from Fe-59-Tf by endothelial cells is inhibited by 50 % when ferrozine is added to solution; in contrast, no inhibition occurs when cells are alkalinized with NH4Cl. This indicates that the iron reduced from holo-transferrin at the plasma membrane accounts for at least 50 % of the iron uptake observed. hBMVEC-dependent reduction and uptake of NTBI utilizes a Pt-II-insensitive reductase. Reductase-independent uptake of Fe-II by hBMVEC is inhibited up to 50 % by Zn-II and/or Mn-II by a saturable process suggesting that redundant Fe-II transporters exist in the hBMVEC plasma membrane. These results are the first to demonstrate multiple mechanism(s) of TBI and NTBI reduction and uptake by endothelial cells (EC) of the BBB.

Cloning and characterization of a novel six-transmembrane protein STEAP2, expressed in normal and malignant prostate

LABORATORY INVESTIGATION

Authors: Porkka, KP; Helenius, MA; Visakorpi, T

By using subtraction and cDNA array hybridizations, we recently identified an anonymous transcript that was differentially expressed in benign prostate hyperplasia and prostate cancer cell line PC-3. Here, we report the cloning of the full-length cDNA of the gene, designated STEAP2 (six-transmembrane epithelial antigen of the prostate 2). The gene is located at the chromosomal region 7q21 and encodes for a 490-amino acid protein with six predicted transmembrane domains and is predominantly expressed in prostate epithelial cells. Green fluorescent protein fusion construct indicated that the STEAP2 protein is localized mainly in the plasma membrane. Real-time quantitative RT-PCR showed that the gene is expressed at levels more than 10 times higher in normal prostate than in other tissues studied. Of the prostate cancer cell lines, STEAP2 was expressed in significant levels only in androgen -responsive LNCaP. The expression of STEAP2 was significantly higher (P = 0.002) in both untreated primary and hormone-refractory prostate carcinomas than in benign prostate hyperplasias, suggesting that it may be involved in the development of prostate cancer. As a cell-surface antigen, STEAP2 is a potential diagnostic or therapeutic target in prostate cancer.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket